GSK's Dan Troy: Mixed Sentiments on Sentinel

FDA has made great progress on its active surveillance project Sentinel. GSK’s top lawyer raises some tough questions for the drug industry to consider as the program advances. Here is an excerpt from his remarks to the third annual workshop on Sentinel, hosted by the Engelberg Center for Health Care Reform at Brookings.